Food Effect Study of D-0502 Tablet in Healthy Volunteers

Study Description

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This is an open label, randomized, balanced, single dose, two-treatment (fed vs. fasting), two-period, two-sequence crossover study of postmenopausal female healthy subjects.

Condition or disease	Intervention/treatment	Phase
Breast Cancer	Drug: D-0502	Phase 1

Study Design

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	14 participants
Allocation:	Randomized
Intervention Model:	Crossover Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase I, Randomized, Open Label, Two-Sequence, Two-Period Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of D-0502 Tablet in Postmenopausal Female Healthy Subjects
Actual Study Start Date :	October 18, 2018
Estimated Primary Completion Date :	January 30, 2019
Estimated Study Completion Date :	June 13, 2019

Arms and Interventions

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Sequence AB; D-0502 Dose Patients will get D-0502 single agent once in the fasted state and once in the fed state.	Drug: D-0502; D-0502 oral tablets
Experimental: Sequence BA; D-0502 Dose Patients will get D-0502 single agent once in the fed state and once in the fasted state.	Drug: D-0502; D-0502 oral tablets

Outcome Measures

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Pharmacokinetic: area under the plasma concentration versus time curve (AUC) [ Time Frame: Day 1 through 4, Day 7 through 11 ]
   AUC: area under the plasma concentration versus time curve for D-0502; Unit: nM*hr
2. Pharmacokinetic: maximum plasma drug concentration (Cmax) [ Time Frame: Day 1 through 4, Day 7 through 11 ]
   Cmax: maximum plasma drug concentration of D-0502; Unit: nM
3. Pharmacokinetic: Time to reach the Cmax (Tmax) [ Time Frame: Day 1 through 4, Day 7 through 11 ]
   Tmax: Time to reach the Cmax of D-0502; Unit: hr
4. Pharmacokinetic: Apparent terminal half-life (t1/2) [ Time Frame: Day 1 through 4, Day 7 through 11 ]
   t1/2: apparent terminal half-life of D-0502; Unit: hr

Secondary Outcome Measures :

1. Incidence of Treatment-Emergent Adverse Events [ Time Frame: 2 weeks ]
   Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Eligibility Criteria

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

1. Subjects must be medically documented as healthy and acceptable at physical examination.
2. Subjects must have a BMI between 18.0 and 32.0 kg/m2 and a body weight of 45 kg or higher.
3. Subjects must have all laboratory parameters within the normal range or considered not clinically significant by the principal investigator.
4. Subjects must have a normal urinalysis, eGFR, ECG or results considered not clinically significant by the principal investigator.

5. Subjects must be female with postmenopausal status defined as meeting at least one of the following criteria:

   1. Have undergone a bilateral oophorectomy any time in life;
   2. Age ≥60 years, or
   3. Age <60 years but have cessation of regular menses ≥12 months with follicle stimulating hormone (FSH) value >40 milli-international units per milliliter (mIU/mL) and an estradiol value <40 picograms per milliliter (pg/mL) (140 picomoles per liter [pmol/L]).
6. Subjects are able to understand the study procedures and risks involved and must provide signed informed consent to participate in the study.

Exclusion Criteria:

1. Subjects with any history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological or psychiatric disorders, as determined by the investigator.
2. Subjects who have any history or suspicion of kidney stones.
3. Subjects who are positive for human immunodeficiency virus (HIV), Hepatitis B, and/or Hepatitis C.
4. Subjects who have used prescription drugs, over-the-counter drugs, or natural health products (including herbal remedies, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 14 days before Day 1 of study medication dosing.
5. Subjects had undergone major surgery within 3 months prior to Day 1.
6. Subjects who is participating in a clinical research study involving the administration of an investigational or marketed drug or device, or who received any investigational test article within 5 half-lives or 30 days prior to Day 1 study medication dosing.
7. Subjects with positive urine drug screen test at screening.
8. Subjects with any condition that, in the judgment of the investigator, would place him/her at undue risk, or potentially compromise the results or interpretation of the study.

Contacts and Locations

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Florida
Covance Daytona Beach Clinical Research Unit
Daytona Beach, Florida, United States, 32117

Sponsors and Collaborators

InventisBio Inc.

More Information

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	InventisBio Inc.
ClinicalTrials.gov Identifier:	NCT03810625 History of Changes
Other Study ID Numbers:	IBIO-302
First Posted:	January 18, 2019
Last Update Posted:	January 18, 2019
Last Verified:	December 2018

Studies a U.S. FDA-regulated Drug Product:		Yes
Studies a U.S. FDA-regulated Device Product:		No